THE European Medicines Agency (EMA) is to review ranitidine (a H2RA) medications after tests revealed some brands contained the carcinogenic N-nitrosodimethylamine.
The Therapeutic Goods Administration has issued a statement about Australian brands - tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Sep 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Sep 19
